Arcus Biosciences Newsroom

BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $23

BofA Securities analyst Jason Zemansky maintains $Arcus Biosciences(RCUS.US)$ with a hold rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 61

Futu NewsSep 16 19:31 · Ratings

Hold Rating on Arcus Biosciences Amid TIGIT Inhibitor Uncertainties

TipRanksSep 16 18:55 · Ratings

Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $25

Barclays analyst Peter Lawson maintains $Arcus Biosciences(RCUS.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 45.0% and

Futu NewsSep 16 15:31 · Ratings

GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial

Seeking AlphaSep 14 19:16

Arcus up 4% Following Merck Welireg Kidney Cancer Data

Seeking AlphaSep 14 03:36

Arcus Biosciences, Inc.'s (NYSE:RCUS) Business And Shares Still Trailing The Industry

Simply Wall StSep 12 23:41

Infinimmune Appoints Dr. Tim Sullivan as Chief Business Officer

BusinesswireSep 3 20:00

Express News | Arcus Biosciences: Facility Adds Operational Flexibility & Provides Funding for Recently Announced Phase 3 Peak-1 Study for Casdatifan.

BreakingsAug 28 04:20

Arcus Biosciences Secures Up to $250 Million Term Loan Facility From Hercules Capital

Market ChameleonAug 28 04:05

Express News | Arcus Biosciences Secures up to $250 Million Term Loan Facility From Hercules Capital

BreakingsAug 28 04:05

Arcus Biosciences Announces New Employment Inducement Grants

BusinesswireAug 27 04:35

Truist Financial Keeps Their Buy Rating on Arcus Biosciences (RCUS)

TipRanksAug 23 19:15 · Ratings

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

BusinesswireAug 22 04:05

Leerink Partners Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $46

Leerink Partners analyst Daina Graybosch maintains $Arcus Biosciences(RCUS.US)$ with a buy rating, and sets the target price at $46.According to TipRanks data, the analyst has a success rate of 31.1%

Futu NewsAug 20 15:32 · Ratings

Arcus Biosciences: A Strong Buy on Promising Drug Pipeline and Anticipated Clinical Milestones

TipRanksAug 20 14:55

Express News | Arcus Biosciences Inc : Leerink Partners Raises Target Price to $46 From $35

BreakingsAug 19 18:33

Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)

TipRanksAug 13 19:35 · Ratings

Truist Financial Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

TipRanksAug 13 19:35

Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating

Truist Financial analyst Asthika Goonewardene maintains $Arcus Biosciences(RCUS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 30.0% and a total average return

Futu NewsAug 13 19:31 · Ratings

Arcus Biosciences Second Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceAug 10 20:14